Nomination Committee for Orexo's Annual General Meeting 2008

Nomination Committee for Orexo's Annual General Meeting 2008

At Orexo AB's Annual General Meeting on April 23, 2007, it was resolved that the
company shall have a Nomination Committee consisting of one representative for
each of the three largest shareholders in terms of the number of votes and the
chairman of the Board of Directors.

Following contacts with the company's three largest shareholders, the following
members have been nominated: 

-Björn Odlander, HealthCap AB, (35.90 percent of capital and votes); 
-Annika Andersson, Fjärde AP-fonden, (9.46 percent of capital and votes); and 
-Bengt Belfrage, Nordea Fonder (5.52 percent of capital and votes). 

In addition thereto, the Nomination Committee consists of Orexo's chairman of
the Board of Directors, Håkan Åström.

The Nomination Committee represents in total approximately 50 per cent of the
capital and votes in the company based on the most recent ownership information
known to Orexo. 

The Nomination Committee's proposals will be presented in the notice for the
Annual General Meeting 2008 and on Orexo's web site, www.orexo.com.

The Annual General Meeting in Orexo AB will be held on Thursday, April 3, 2008
in Stockholm, Sweden. 

For further information, please contact: 
Zsolt Lavotha, President and CEO, Orexo AB 
+46 (0)18 780 88 12, e-mail: zsolt.lavotha@orexo.se
Claes Wenthzel, Executive Vice President and CFO, Orexo AB 
+46 (0)18 780 88 44, e-mail: claes.wenthzel@orexo.se

TO THE EDITORS 

About Orexo 

Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo's drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs.

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets. 

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase, one in clinical phase I, one in
formulation phase and two in early development phase. 

Orexo is listed on the Nordic List at the OMX Nordic Exchange Stockholm, Mid Cap
(ticker: ORX). 

www.orexo.com